# Article information:

ILT4 functions as a potential checkpoint molecule for tumor immunotherapy - PubMed
<https://pubmed.ncbi.nlm.nih.gov/29649510/>

# Article summary:

1. ILT4 is a novel checkpoint molecule that can be targeted for tumor immunotherapy.

2. ILT4 is expressed in the tumor microenvironment of various malignancies and modulates the biological behaviors of tumor cells, promoting their immune escape.

3. This review explores the functional role of ILT4 as a checkpoint molecule in cancers and discusses its potential role as an immune checkpoint target for tumor immunotherapy.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article provides a comprehensive overview of the potential role of ILT4 as a novel checkpoint molecule for cancer immunotherapy. The authors provide evidence from recent studies to support their claims, which makes the article reliable and trustworthy. However, there are some points that could have been explored further or discussed more thoroughly. For example, while the authors discuss how ILT4 can impair effector anti-tumor immune responses, they do not provide any evidence to support this claim or explore possible counterarguments. Additionally, while the authors discuss how ILT4 can sustain the tumor suppressive microenvironment, they do not provide any evidence to support this claim or explore possible counterarguments either. Furthermore, while the authors mention that improved understanding of these issues is critical for elucidation of the role of ILT4 in tumor pathogenesis, they do not provide any evidence to support this claim or explore possible counterarguments either. Additionally, while the authors mention that targeting this novel and alternative checkpoint molecule could open new avenues for cancer immunotherapy, they do not provide any evidence to support this claim or explore possible counterarguments either. All in all, while this article provides an informative overview on ILT4 as a potential checkpoint molecule for cancer immunotherapy, it could have been more thorough in exploring all aspects related to its potential use in cancer treatment and providing evidence to back up its claims.

# Topics for further research:

* ILT4 cancer immunotherapy clinical trials
* ILT4 effector anti-tumor immune responses
* ILT4 tumor suppressive microenvironment
* ILT4 role in tumor pathogenesis
* Targeting ILT4 for cancer immunotherapy
* ILT4 checkpoint molecule cancer treatment

# Report location:

<https://www.fullpicture.app/item/88d0cea390db5b90257f42fa3ea0ad87>